Strategic Partnerships Triana’s target-first molecular glue platform with a cancer focus suggests strong appeal for discovery collaborations and licensing deals with CROs, biotech partners, and academic labs. The company already runs internal lab work and maintains external collaborations, signaling openness to joint programs across early discovery, preclinical, and translational stages. Engage with senior scientific and business leaders (CSO, CDO) to explore co-discovery, sponsored research, or platform-access partnerships that could accelerate undruggable target programs.

Development Leadership Recent leadership hires as Chief Development Officer and Chief Operating Officer indicate a deliberate push to scale development operations. This creates a window to offer end-to-end development support, including translational science, regulatory strategy, CMC manufacturing, and GMP/IND-enabling services. Position as a preferred development partner for oncology programs aligned to TRIANA’s pipeline, with clear milestones and integrated program management.

Clinical Pipeline AACR 2026 presentation of TRI-611 signals an active near-term clinical asset and data generation plan. Opportunities exist to support translational research, biomarker strategy, companion diagnostics, PK/PD modeling, and trial-ready material production ahead of IND or early-phase studies. Propose collaboration paths for IND-enabling studies, GLP toxicology, clinical assay development, or scalable supply of clinical-grade compounds.

Funding Momentum Significant Series B funding and venture backing show momentum and capital availability to accelerate partnerships. This opens doors for platform licensing, co-development agreements, or sponsored research that leverages Triana’s molecular glue platform to tackle additional targets. Frame conversations around de-risked collaboration models and value-based milestones attractive to both the company and potential investors.

Local Ecosystem Strategic location in Massachusetts’ biotech corridor offers proximity to top universities, pharma partners, and a ready CRO/CMO network. Leverage local ecosystem for academic collaborations, pilot-scale manufacturing, preclinical services, and rapid supplier relationships. Propose local joint development programs and on-site or nearby pilot facilities to streamline timelines.